JP2005531614A - ワクチン組成物 - Google Patents

ワクチン組成物 Download PDF

Info

Publication number
JP2005531614A
JP2005531614A JP2004512791A JP2004512791A JP2005531614A JP 2005531614 A JP2005531614 A JP 2005531614A JP 2004512791 A JP2004512791 A JP 2004512791A JP 2004512791 A JP2004512791 A JP 2004512791A JP 2005531614 A JP2005531614 A JP 2005531614A
Authority
JP
Japan
Prior art keywords
vesicle
meningococcal
strain
vesicles
bactericidal activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004512791A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005531614A5 (enExample
Inventor
バーベラ，モラレス，ラモン，ファウスティノ
デスモン，ピエール，ミッシェル
アルヴァレス，フランシスコ，ヘサス ドミンゲス
プールマン，ジャン
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
インスティチュート フィンレイ，セントロ デ インヴェスティゲション−プロダクシオン デ スエロス イ ヴァキュナス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム, インスティチュート フィンレイ，セントロ デ インヴェスティゲション−プロダクシオン デ スエロス イ ヴァキュナス filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2005531614A publication Critical patent/JP2005531614A/ja
Publication of JP2005531614A5 publication Critical patent/JP2005531614A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2004512791A 2002-06-13 2003-06-10 ワクチン組成物 Pending JP2005531614A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0213622.4A GB0213622D0 (en) 2002-06-13 2002-06-13 Vaccine Corporation
PCT/EP2003/006094 WO2003105890A2 (en) 2002-06-13 2003-06-10 Vaccine composition

Publications (2)

Publication Number Publication Date
JP2005531614A true JP2005531614A (ja) 2005-10-20
JP2005531614A5 JP2005531614A5 (enExample) 2006-07-27

Family

ID=9938532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004512791A Pending JP2005531614A (ja) 2002-06-13 2003-06-10 ワクチン組成物

Country Status (20)

Country Link
US (1) US20060110412A1 (enExample)
EP (1) EP1565211A2 (enExample)
JP (1) JP2005531614A (enExample)
KR (1) KR20050049431A (enExample)
CN (1) CN100387298C (enExample)
AR (1) AR040204A1 (enExample)
AU (1) AU2003236734A1 (enExample)
BR (1) BR0311777A (enExample)
CA (1) CA2488782A1 (enExample)
CL (1) CL2003001192A1 (enExample)
CU (1) CU23552A1 (enExample)
GB (1) GB0213622D0 (enExample)
MX (1) MXPA04012568A (enExample)
NO (1) NO20050132L (enExample)
NZ (1) NZ560766A (enExample)
PE (1) PE20040562A1 (enExample)
RU (1) RU2005100509A (enExample)
UY (1) UY27843A1 (enExample)
WO (1) WO2003105890A2 (enExample)
ZA (1) ZA200409547B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511275A (ja) * 2008-02-01 2011-04-07 サノフィ パストゥール リミテッド 診断的アッセイ
JP2013507354A (ja) * 2009-10-08 2013-03-04 イオン メディックス インコーポレイテッド 室内空気由来細胞外ベシクルを含む組成物及びその用途
JP2016104776A (ja) * 2009-12-22 2016-06-09 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 免疫原性組成物

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030024811A (ko) 2000-07-27 2003-03-26 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
BRPI0607374B8 (pt) 2005-01-27 2021-05-25 Childrens Hospital & Res Center At Oakland vacinas de vesículas baseadas em gna1870 para proteção de amplo espectro contra doenças causadas por neisseria meningitidis
CA2808919C (en) * 2005-12-22 2016-04-19 Glaxosmithkline Biologicals S.A. Streptococcus pneumoniae capsular saccharide vaccine
SI2097102T1 (sl) 2006-09-07 2012-09-28 Glaxosmithkline Biolog Sa Kombinirano cepivo, ki ima zmanjšane količine antigena za poliovirus
CA2702871A1 (en) 2007-10-19 2009-04-23 Novartis Ag Meningococcal vaccine formulations
JP2011503104A (ja) 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー 免疫調節化合物ならびに関連組成物および方法
DK2268618T3 (en) 2008-03-03 2015-08-17 Novartis Ag Compounds and compositions as TLR aktivitetsmodulatorer
NZ593674A (en) 2008-12-17 2013-03-28 Novartis Ag Meningococcal vaccines including hemoglobin receptor
EP2440245B1 (en) 2009-06-10 2017-12-06 GlaxoSmithKline Biologicals SA Benzonaphthyridine-containing vaccines
AU2010288239B2 (en) 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
MX339146B (es) 2009-12-15 2016-05-13 Novartis Ag Suspension homogenea de compuestos inmunopotenciadores y usos de los mismos.
EP2547357A1 (en) 2010-03-18 2013-01-23 Novartis AG Adjuvanted vaccines for serogroup b meningococcus
EP2549990A1 (en) 2010-03-23 2013-01-30 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
WO2011127302A2 (en) * 2010-04-07 2011-10-13 Yue Shen Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
US9259462B2 (en) * 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
EP2707009A1 (en) 2011-05-12 2014-03-19 Novartis AG Antipyretics to enhance tolerability of vesicle-based vaccines
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-BASED PSA COMPOSITIONS, METHOD FOR THEIR INSULATION AND USE METHOD THEREFOR
ES2654613T3 (es) 2012-02-02 2018-02-14 Glaxosmithkline Biologicals Sa Promotores para una expresión aumentada de proteínas en meningococos
JP2015517089A (ja) 2012-03-08 2015-06-18 ノバルティス アーゲー タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ
US10376573B2 (en) 2012-06-14 2019-08-13 Glaxosmithkline Biologicals Sa Vaccines for serogroup X meningococcus
AU2013311702A1 (en) 2012-09-06 2015-02-19 Novartis Ag Combination vaccines with serogroup B meningococcus and D/T/P
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
EP3337321A4 (en) 2015-08-19 2019-07-17 President and Fellows of Harvard College LIPIDED PSA COMPOSITIONS AND METHOD
EP3484441A4 (en) 2016-07-15 2020-03-18 President and Fellows of Harvard College GLYCOLIPID COMPOSITIONS AND METHOD FOR USE
CA3035320A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
CA3166272A1 (en) * 2020-10-23 2022-04-28 Omvax, Inc. Compositions and methods for vaccination against neisseria gonorrhoeae
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL338146A1 (en) * 1997-07-17 2000-09-25 North American Vaccine Immunogenic complex combinations consisting of meningococcal porine of b group and h. influenzae polysaccharide
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
KR20030024811A (ko) * 2000-07-27 2003-03-26 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511275A (ja) * 2008-02-01 2011-04-07 サノフィ パストゥール リミテッド 診断的アッセイ
JP2013507354A (ja) * 2009-10-08 2013-03-04 イオン メディックス インコーポレイテッド 室内空気由来細胞外ベシクルを含む組成物及びその用途
JP2016104776A (ja) * 2009-12-22 2016-06-09 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 免疫原性組成物

Also Published As

Publication number Publication date
KR20050049431A (ko) 2005-05-25
MXPA04012568A (es) 2005-09-21
US20060110412A1 (en) 2006-05-25
WO2003105890A3 (en) 2004-03-25
CN1668329A (zh) 2005-09-14
NO20050132D0 (no) 2005-01-11
CN100387298C (zh) 2008-05-14
CU23552A1 (es) 2010-07-20
AU2003236734A1 (en) 2003-12-31
NZ560766A (en) 2009-09-25
GB0213622D0 (en) 2002-07-24
ZA200409547B (en) 2006-07-26
CA2488782A1 (en) 2003-12-24
BR0311777A (pt) 2005-03-29
CL2003001192A1 (es) 2005-01-07
PE20040562A1 (es) 2004-10-19
RU2005100509A (ru) 2006-06-10
AR040204A1 (es) 2005-03-16
UY27843A1 (es) 2003-12-31
NO20050132L (no) 2005-02-11
WO2003105890A2 (en) 2003-12-24
EP1565211A2 (en) 2005-08-24

Similar Documents

Publication Publication Date Title
CN100387298C (zh) 疫苗组合物
TWI360424B (en) Vaccine
JP5275983B2 (ja) ワクチン
US20050244436A1 (en) Combination Neisserial compositions
JP2017114874A (ja) 免疫原性組成物
Zollinger et al. Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine
Pinto et al. An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups
EP1572729B1 (en) Mutant frpb protein and refolding method
EP1532168A2 (en) Method for refolding neisserial nspa protein
RU2359696C2 (ru) Вакцинная композиция, содержащая трансферрин-связывающий белок и hsf из грамотрицательных бактерий
AU2016228231A1 (en) Combination Neisserial compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091224

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101102